OBJECTIVE: To report the outcome of over 1000 men with low risk prostate cancer treated with low dose rate brachytherapy at three large UK cancer centres.
METHODS: 1038 patients with low risk prostate cancer (PSA ≤ 10ng/ml, Gleason score =6, ≤ T2b disease) were treated with low dose rate iodine 125 brachytherapy between 2002 and 2007. Patients were treated at three UK centres PSA and clinical follow up was performed at each centre. Biochemical recurrence free survival is reported for the group.
RESULTS: Median PSA follow up for the whole group was 5.0 years (range 4 months - 9 years). 79 patients had a biochemical failure defined by a rise in PSA; 16 fulfilled the ASTRO definition of biochemical failure, 25 the Phoenix definition and 38 patients fulfilled with both definitions. The 5-year biochemical relapse free survival (bRFS) was 94.1% by the ASTRO definition and 94.2% by the Phoenix definition. The absence of neoadjuvant hormone therapy was predictive of inferior biochemical control as defined by the Phoenix definition (p=0.033).
CONCLUSION: Our prospective multicentre series has demonstrated excellent biochemical relapse free survival (bRFS) with LDR I-125 brachytherapy for patients with low risk prostate cancer. Further work is necessary to define the role of neoadjuvant androgen deprivation therapy in combination with brachytherapy.
Written by:
Dickinson P, Malik J, Mandall P, Swindell R, Bottomley D, Hoskin P, Logue J, Wylie J. Are you the author?
Reference: BJU Int. 2013 Jul 8. Epub ahead of print.
doi: 10.1111/bju.12358
PubMed Abstract
PMID: 24053230
UroToday.com Prostate Cancer Section
